Aerie executes succession plan to separate CEO, chairman roles
Benjamin F. McGraw III, PharmD, has been appointed as the interim executive chairman of the board of directors at Aerie Pharmaceuticals, replacing Vicente Anido Jr., PhD, the former chairman and CEO, according to a press release.
“All of our employees appreciate Vince’s leadership, which has guided us through two FDA and EMA product approvals while building a manufacturing facility and a robust pipeline of products, leaving our company in great shape for the future,” Thomas A. Mitro, president and chief operating officer at Aerie, told Healio/OSN.
Aerie intends to separate the roles of chairman and CEO, according to the release, and a search is underway for a new CEO.
“It’s been an exciting experience making Dr. David Epstein’s dream of developing a unique glaucoma product that treats the underlying causes of the disease a reality. Many thanks to the Aerie team for the great memories,” Anido said in the release.
“On behalf of the board, I would like to express our sincere appreciation to Vince for all his contributions over the years since Aerie was a private company through the public offering and into Aerie becoming a commercial stage company,” McGraw said in the release.